Cargando…

Pancreatic Diffuse Large B-cell Lymphoma in the US Population

Background: Pancreatic lymphomas (PLs) represent <2% of all lymphomas and <0.5% of all pancreatic neoplasms. An accurate histologic diagnosis of PL is needed to predict prognosis and adequately treat the patient. This study aims to investigate the demographic, clinical, and pathological factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ullah, Asad, Lee, Kue T, Malham, Kali, Yasinzai, Abdul Qahar Khan, Tareen, Bisma, Lopes, Dara, Wali, Agha, Velasquez Zarate, Luis, Waheed, Abdul, Wiest, Maya, Hakim, Resham, Khan, Marjan, Asif, Bina, Patel, Nikhil, Hakim, Sahar, Kakar, Kaleemullah, Heneidi, Saleh, Karki, Nabin R, Sidhwa, Feroze
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315061/
https://www.ncbi.nlm.nih.gov/pubmed/37404424
http://dx.doi.org/10.7759/cureus.39862
_version_ 1785067434545250304
author Ullah, Asad
Lee, Kue T
Malham, Kali
Yasinzai, Abdul Qahar Khan
Tareen, Bisma
Lopes, Dara
Wali, Agha
Velasquez Zarate, Luis
Waheed, Abdul
Wiest, Maya
Hakim, Resham
Khan, Marjan
Asif, Bina
Patel, Nikhil
Hakim, Sahar
Kakar, Kaleemullah
Heneidi, Saleh
Karki, Nabin R
Sidhwa, Feroze
author_facet Ullah, Asad
Lee, Kue T
Malham, Kali
Yasinzai, Abdul Qahar Khan
Tareen, Bisma
Lopes, Dara
Wali, Agha
Velasquez Zarate, Luis
Waheed, Abdul
Wiest, Maya
Hakim, Resham
Khan, Marjan
Asif, Bina
Patel, Nikhil
Hakim, Sahar
Kakar, Kaleemullah
Heneidi, Saleh
Karki, Nabin R
Sidhwa, Feroze
author_sort Ullah, Asad
collection PubMed
description Background: Pancreatic lymphomas (PLs) represent <2% of all lymphomas and <0.5% of all pancreatic neoplasms. An accurate histologic diagnosis of PL is needed to predict prognosis and adequately treat the patient. This study aims to investigate the demographic, clinical, and pathological factors affecting the prognosis and survival of pancreatic diffuse large B-cell lymphoma (DLBCL). Methods: Demographic and clinical data from 493 cases of DLBCL of the pancreas were identified between 2000 and 2018 using the Surveillance, Epidemiology, and End Results (SEER) database. Results: The most common age group was between the ages of 70 and 79 years (27.0%). While 44% of cases involved distant sites (a proxy for secondary pancreatic DLBCL), regional and localized involvement was seen in 33%, with the most common cause of death being a primary pancreatic DLBCL. Most patients (71%) received only chemotherapy (systemic therapy). The overall five-year observed survival was 46% (95% CI, 43.5-48.3). The one-year and five-year survival with chemotherapy only was 68% (95% CI, 65.3-70.3) and 48% (95% CI, 44.7-50.5), respectively. The one-year and five-year survival with surgery and chemotherapy was 96% (95% CI, 91.3-99.9) and 80% (95% CI, 71.4-89.2), respectively. Surgery with chemotherapy (HR: 0.397 (95% CI, 0.197-0.803), p = 0.010) were both positive predictors in survival prognosis. Multivariable analysis identified age >55 years (HR: 2.475 (95% CI, 1.770-3.461), p < 0.001), distant stage (HR: 6.894 (95% CI, 4.121-11.535), p < 0.001), and undergoing no surgery (HR: 2.610 (95% CI, 1.307-5.215), p = 0.007) as negative predictors for survival. Conclusion: PLs are rare malignant pancreatic neoplasms with DLBCL being the most common histological subtype. An accurate and timely diagnosis of pancreatic DLBCL is necessary to implement effective treatments and reduce mortality. Systemic therapy (chemotherapy) with or without surgical therapy improved survival. Increased age and regional and distant spread negatively impacted survival.
format Online
Article
Text
id pubmed-10315061
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-103150612023-07-03 Pancreatic Diffuse Large B-cell Lymphoma in the US Population Ullah, Asad Lee, Kue T Malham, Kali Yasinzai, Abdul Qahar Khan Tareen, Bisma Lopes, Dara Wali, Agha Velasquez Zarate, Luis Waheed, Abdul Wiest, Maya Hakim, Resham Khan, Marjan Asif, Bina Patel, Nikhil Hakim, Sahar Kakar, Kaleemullah Heneidi, Saleh Karki, Nabin R Sidhwa, Feroze Cureus Pathology Background: Pancreatic lymphomas (PLs) represent <2% of all lymphomas and <0.5% of all pancreatic neoplasms. An accurate histologic diagnosis of PL is needed to predict prognosis and adequately treat the patient. This study aims to investigate the demographic, clinical, and pathological factors affecting the prognosis and survival of pancreatic diffuse large B-cell lymphoma (DLBCL). Methods: Demographic and clinical data from 493 cases of DLBCL of the pancreas were identified between 2000 and 2018 using the Surveillance, Epidemiology, and End Results (SEER) database. Results: The most common age group was between the ages of 70 and 79 years (27.0%). While 44% of cases involved distant sites (a proxy for secondary pancreatic DLBCL), regional and localized involvement was seen in 33%, with the most common cause of death being a primary pancreatic DLBCL. Most patients (71%) received only chemotherapy (systemic therapy). The overall five-year observed survival was 46% (95% CI, 43.5-48.3). The one-year and five-year survival with chemotherapy only was 68% (95% CI, 65.3-70.3) and 48% (95% CI, 44.7-50.5), respectively. The one-year and five-year survival with surgery and chemotherapy was 96% (95% CI, 91.3-99.9) and 80% (95% CI, 71.4-89.2), respectively. Surgery with chemotherapy (HR: 0.397 (95% CI, 0.197-0.803), p = 0.010) were both positive predictors in survival prognosis. Multivariable analysis identified age >55 years (HR: 2.475 (95% CI, 1.770-3.461), p < 0.001), distant stage (HR: 6.894 (95% CI, 4.121-11.535), p < 0.001), and undergoing no surgery (HR: 2.610 (95% CI, 1.307-5.215), p = 0.007) as negative predictors for survival. Conclusion: PLs are rare malignant pancreatic neoplasms with DLBCL being the most common histological subtype. An accurate and timely diagnosis of pancreatic DLBCL is necessary to implement effective treatments and reduce mortality. Systemic therapy (chemotherapy) with or without surgical therapy improved survival. Increased age and regional and distant spread negatively impacted survival. Cureus 2023-06-02 /pmc/articles/PMC10315061/ /pubmed/37404424 http://dx.doi.org/10.7759/cureus.39862 Text en Copyright © 2023, Ullah et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pathology
Ullah, Asad
Lee, Kue T
Malham, Kali
Yasinzai, Abdul Qahar Khan
Tareen, Bisma
Lopes, Dara
Wali, Agha
Velasquez Zarate, Luis
Waheed, Abdul
Wiest, Maya
Hakim, Resham
Khan, Marjan
Asif, Bina
Patel, Nikhil
Hakim, Sahar
Kakar, Kaleemullah
Heneidi, Saleh
Karki, Nabin R
Sidhwa, Feroze
Pancreatic Diffuse Large B-cell Lymphoma in the US Population
title Pancreatic Diffuse Large B-cell Lymphoma in the US Population
title_full Pancreatic Diffuse Large B-cell Lymphoma in the US Population
title_fullStr Pancreatic Diffuse Large B-cell Lymphoma in the US Population
title_full_unstemmed Pancreatic Diffuse Large B-cell Lymphoma in the US Population
title_short Pancreatic Diffuse Large B-cell Lymphoma in the US Population
title_sort pancreatic diffuse large b-cell lymphoma in the us population
topic Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315061/
https://www.ncbi.nlm.nih.gov/pubmed/37404424
http://dx.doi.org/10.7759/cureus.39862
work_keys_str_mv AT ullahasad pancreaticdiffuselargebcelllymphomaintheuspopulation
AT leekuet pancreaticdiffuselargebcelllymphomaintheuspopulation
AT malhamkali pancreaticdiffuselargebcelllymphomaintheuspopulation
AT yasinzaiabdulqaharkhan pancreaticdiffuselargebcelllymphomaintheuspopulation
AT tareenbisma pancreaticdiffuselargebcelllymphomaintheuspopulation
AT lopesdara pancreaticdiffuselargebcelllymphomaintheuspopulation
AT waliagha pancreaticdiffuselargebcelllymphomaintheuspopulation
AT velasquezzarateluis pancreaticdiffuselargebcelllymphomaintheuspopulation
AT waheedabdul pancreaticdiffuselargebcelllymphomaintheuspopulation
AT wiestmaya pancreaticdiffuselargebcelllymphomaintheuspopulation
AT hakimresham pancreaticdiffuselargebcelllymphomaintheuspopulation
AT khanmarjan pancreaticdiffuselargebcelllymphomaintheuspopulation
AT asifbina pancreaticdiffuselargebcelllymphomaintheuspopulation
AT patelnikhil pancreaticdiffuselargebcelllymphomaintheuspopulation
AT hakimsahar pancreaticdiffuselargebcelllymphomaintheuspopulation
AT kakarkaleemullah pancreaticdiffuselargebcelllymphomaintheuspopulation
AT heneidisaleh pancreaticdiffuselargebcelllymphomaintheuspopulation
AT karkinabinr pancreaticdiffuselargebcelllymphomaintheuspopulation
AT sidhwaferoze pancreaticdiffuselargebcelllymphomaintheuspopulation